Arrow Dx’s Post

“When things start to go wrong for patients with liver disease, it can go wrong very, very quickly.” The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising. In light of the stark unmet needs in liver disease treatment — particularly for metabolic dysfunction-associated steatohepatitis (MASH) — there’s a pressing need for more sites equipped to effectively support advanced liver disease research. As Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, highlights in this video, there’s reason to be optimistic if we can carry momentum from recent hepatology breakthroughs further into MASH treatment. With the expertise of leaders Dr. Kowdley, Nadege Gunn, MD, CPI, J. Scott Overcash, M.D., and Lauri Befus, Velocity’s MASH Council to Accelerate Research Excellence (CARE) will deliver world-class operational, recruitment, and trial conduct oversight to all Velocity sites conducting MASH trials. #MASH #MASLD #Hepatology #CARECouncil

Are you attending the European Congress on Obesity in May? Don't miss the chance to meet #Perspectum's Pharma Solutions team! Book and appointment with one of our team members to learn about our leadership in using imaging to identify and monitor multi-organ disease in clincal trials. Let us help you revolutionize your approach to clinical trials in obesity-related liver diseases. See you there! #ECO24 #clinicaltrials

Dear Colleagues, A recent publication in the American Journal of Case Reports sheds light on an intriguing case of intrahepatic cholangiocarcinoma in a patient with Wilson's disease. This rare autosomal recessive disorder, characterized by copper accumulation, presents a range of clinical manifestations. With only 14 reported cases, the link between Wilson's disease and hepatobiliary malignancies remains unclear. The successful treatment of the patient through resection and adjuvant chemotherapy highlights the importance of careful monitoring and tailored treatment strategies for favorable outcomes. This case report prompts further exploration into the potential occurrence of intrahepatic cholangiocarcinoma in Wilson's disease. The complete report is now available on the American Journal of Case Reports webpage. | https://lnkd.in/dmxC3KUd

Taking a closer look at #systemic #thrombolysis for acute portal vein #thrombosis in cirrhotic patients. Understanding the varying prevalence in different stages of liver disease is key. Dive into the details here: https://bit.ly/3WZa0O9 #Sonography #Cirrhosis #LiverDisease

Dear Colleagues, A recent publication in the American Journal of Case Reports sheds light on an intriguing case of intrahepatic cholangiocarcinoma in a patient with Wilson's disease. This rare autosomal recessive disorder, characterized by copper accumulation, presents a range of clinical manifestations. With only 14 reported cases, the link between Wilson's disease and hepatobiliary malignancies remains unclear. The successful treatment of the patient through resection and adjuvant chemotherapy highlights the importance of careful monitoring and tailored treatment strategies for favorable outcomes. This case report prompts further exploration into the potential occurrence of intrahepatic cholangiocarcinoma in Wilson's disease. The complete report is now available on the American Journal of Case Reports webpage. | https://lnkd.in/dntvdm8Q

Rare Disease Day presents an opportunity to highlight significant advancements in #genomicmedicine, recognize the challenges associated with living with and treating #rarediseases, and evaluate the readiness of European #healthsystems to provide #access to cutting-edge #treatments for #patients. 🧬 This article, spearheaded by the Alliance for Regenerative Medicine (ARM) in partnership with the Thalassaemia International Federation - TIF and Fondazione Telethon, examines the crucial opportunity for the EU to develop a forward-looking framework that can realize the promise of #innovativetherapies for patients—a potential that must not be left untapped. https://lnkd.in/eSGdj-D4

April 19th is #WorldLiverDay and the A-TANGO consortium stands for the continued and necessary fight against acute-on-chronic liver failure (#ACLF). At the moment, there are barely any treatment options for patients suffering from late-stage #cirrhosis, a condition that is responsible for approximately 2.4% of the deaths worldwide (per year) and can have various causes - including bacterial or viral #infections, non-alcoholic fatty liver disease (NAFLD), and alcohol abuse.  Currently, up to 40% of patients who come to the hospital with decompensated cirrhosis (interpretable as an acute phase of ACLF) succumb to the disease and die. A-TANGO strives to increase the survival rate of these patients with "G-TAK", a novel, #CombinatorialTherapy. Also, 30% of ACLF patients recover only partially, remaining in need of expensive long-term care. By improving the percentage of patients recovering fully, A-TANGO also aims to decrease the burden on the national #HealthcareSystems. European Foundation for the Study of Chronic Liver Failure (EF CLIF) Charité - Universitätsmedizin Berlin concentris research management GmbH Crowdhelix EASL | The Home of Hepatology European Liver Patients' Association - ELPA Greater Paris University Hospitals - AP-HP Hepyx Leipzig University Leiden University Medical Center UCL Yaqrit Rajiv Jalan Cornelius Engelmann Mohsin Hassan Ingrid Zhang Wouter Kruijs Ben Hainsworth Marko Korenjak Veronika Všetíčková Thomas Berg Pr. Isabelle Durand-Zaleski Fausto Andreola Minneke Coenraad Daniel Green Michal Kowalski Karen Galvin Burcu Kiper Michael Browne Arthur Mulle Dr. Ameli Schwalber Tamara Breitinger Nicole Tunstall

I'm happy to share the first publication of my PhD! 😊 In this review, we present the most relevant in vitro models of inflammatory bowel disease. The development of reliable and predictable 3D models holds promise in bridging the gap between in vitro and in vivo testing, potentially revolutionizing drug development and aligning with the 3Rs policy. Furthermore, these models provide valuable tools for assessing the therapeutic efficacy of different nanotherapies. #invitromodels #inflammatoryboweldisease #genegut

We are thrilled to announce that VCTE™, our original and proprietary #FibroScan® technology to measure liver stiffness, is recommended with the specific cut-off value of 8 kPa in the stepwise strategy for non-invasive assessment of the risk for advanced fibrosis in the new EASL–EASD–EASO Clinical Practice Guidelines on the management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Pioneer and leader in its field, Echosens, significantly changed the practice of liver assessment with FibroScan®, the only device with VCTE™ technology and clear cut-off values for risk stratification along the patient care continuum. FibroScan® is recognized worldwide and validated by over 4,200 peer-reviewed publications and 180+ international guidelines. #LiverHealthMatters EASL | The Home of Hepatology European Association for the Study of Diabetes e.V. (EASD) European Association for the Study of Obesity (EASO)

It is with these clear cutoffs that we use in #MASLD that offer greater opportunities to locate and deliver care to the #patient Supporting #physician decisions in managment.